Jane Street Group, LLC Fibrogen Inc Call Options Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 17, 2022	BUY	$12.02 - $16.79 $126,210 - $176,295	10,500 Added 22.93%	56,300 $677,000
Q4 2021 Feb 15, 2022	BUY	$9.93 - $15.39 $141,006 - $218,538	14,200 Added 44.94%	45,800 $646,000
Q3 2021 Nov 16, 2021	SELL	$10.18 - $26.64 $3.74 Million - $9.78 Million	-367,000 Reduced 92.07%	31,600 $323,000
Q2 2021 Aug 16, 2021	BUY	$18.57 - $35.68 $7.25 Million - $13.9 Million	390,500 Added 4820.99%	398,600 $10.6 Million
Q1 2021 May 18, 2021	SELL	$31.0 - $55.72 $6.32 Million - $11.4 Million	-203,800 Reduced 96.18%	8,100 $281,000
Q4 2020 Feb 17, 2021	BUY	$37.09 - $48.97 $7.05 Million - $9.31 Million	190,100 Added 872.02%	211,900 $7.86 Million
Q3 2020 Nov 17, 2020	SELL	$40.47 - $45.5 $724,413 - $814,450	-17,900 Reduced 45.09%	21,800 $896,000
Q2 2020 Aug 17, 2020	BUY	$32.57 - $42.83 $1.29 Million - $1.7 Million	39,700 New	39,700 $1.61 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $46.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.